JP5755731B2 - Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド - Google Patents

Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド Download PDF

Info

Publication number
JP5755731B2
JP5755731B2 JP2013513340A JP2013513340A JP5755731B2 JP 5755731 B2 JP5755731 B2 JP 5755731B2 JP 2013513340 A JP2013513340 A JP 2013513340A JP 2013513340 A JP2013513340 A JP 2013513340A JP 5755731 B2 JP5755731 B2 JP 5755731B2
Authority
JP
Japan
Prior art keywords
alkyl
group
cyclopenta
pentamethyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013513340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527243A (ja
JP2013527243A5 (enExample
Inventor
アリシア・レゲイロ−レン
チェン・リウ
ジェイコブ・スウィドースキ
ニコラス・エイ・ミーンウェル
シン−ユエン・シット
チェン・ジエ
ヤン・チェン
ナイ・シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013527243A publication Critical patent/JP2013527243A/ja
Publication of JP2013527243A5 publication Critical patent/JP2013527243A5/ja
Application granted granted Critical
Publication of JP5755731B2 publication Critical patent/JP5755731B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013513340A 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド Expired - Fee Related JP5755731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35133210P 2010-06-04 2010-06-04
US61/351,332 2010-06-04
PCT/US2011/038884 WO2011153319A1 (en) 2010-06-04 2011-06-02 C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (3)

Publication Number Publication Date
JP2013527243A JP2013527243A (ja) 2013-06-27
JP2013527243A5 JP2013527243A5 (enExample) 2014-07-17
JP5755731B2 true JP5755731B2 (ja) 2015-07-29

Family

ID=44627254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513340A Expired - Fee Related JP5755731B2 (ja) 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド

Country Status (20)

Country Link
US (1) US8802661B2 (enExample)
EP (1) EP2576586B1 (enExample)
JP (1) JP5755731B2 (enExample)
CN (1) CN102985438B (enExample)
AR (1) AR081638A1 (enExample)
BR (1) BR112012030810A2 (enExample)
CA (1) CA2801491C (enExample)
DK (1) DK2576586T3 (enExample)
EA (1) EA026140B1 (enExample)
ES (1) ES2548905T3 (enExample)
HR (1) HRP20150977T1 (enExample)
HU (1) HUE026662T2 (enExample)
MX (1) MX2012013628A (enExample)
PL (1) PL2576586T3 (enExample)
PT (1) PT2576586E (enExample)
RS (1) RS54239B1 (enExample)
SI (1) SI2576586T1 (enExample)
SM (1) SMT201500272B (enExample)
TW (1) TW201201792A (enExample)
WO (1) WO2011153319A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103339141B (zh) * 2011-01-31 2016-08-24 百时美施贵宝公司 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺
ES2653847T3 (es) * 2011-01-31 2018-02-09 Viiv Healthcare Uk (No. 4) Limited Triterpenoides C-17 y C-3 modificados con actividad inhibitoria contra maduración del VIH
ES2611727T3 (es) 2011-09-21 2017-05-10 VIIV Healthcare UK (No.5) Limited Derivados de ácido betulínico novedosos con actividad antivírica
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
JP6186010B2 (ja) * 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
KR20150121712A (ko) * 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
MA39374A1 (fr) 2014-04-11 2018-06-29 Viiv Healthcare Uk No 4 Ltd Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
WO2015198263A2 (en) * 2014-06-26 2015-12-30 Hetero Research Foundation Novel betulinic proline substituted derivatives as hiv inhibitors
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
CN108368071A (zh) * 2015-09-24 2018-08-03 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的化合物
CN108699103A (zh) 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2019207460A1 (en) 2018-04-24 2019-10-31 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
ATE348839T1 (de) * 1998-03-02 2007-01-15 Univ North Carolina Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
NZ538896A (en) * 2002-09-26 2007-10-26 Niigata University Of Pharmacy Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
JP2007529544A (ja) 2004-03-17 2007-10-25 パナコス ファーマシューティカルズ, インコーポレイテッド 3−o−(3’,3’−ジメチルスクシニル)ベツリン酸の製薬的な塩
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
US7282521B2 (en) * 2004-05-24 2007-10-16 University Of North Carolina At Chapel Hill Anti-retroviral moronic acid derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP1986654A2 (en) * 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
WO2008097341A2 (en) * 2006-07-26 2008-08-14 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
US20090062243A1 (en) * 2007-08-03 2009-03-05 Advanced Life Sciences, Inc. Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
SI2271658T1 (sl) * 2008-04-18 2017-03-31 Reata Pharmaceuticals, Inc. Antioksidantni modulatorji vnetja: C-17 homologirani derivati oleanolne kisline
KR20120138761A (ko) * 2010-02-11 2012-12-26 글락소스미스클라인 엘엘씨 베툴린의 유도체

Also Published As

Publication number Publication date
EP2576586B1 (en) 2015-08-12
MX2012013628A (es) 2012-12-17
EA026140B1 (ru) 2017-03-31
BR112012030810A2 (pt) 2019-09-24
HRP20150977T1 (hr) 2015-10-09
CN102985438B (zh) 2016-05-18
PT2576586E (pt) 2015-10-23
AR081638A1 (es) 2012-10-10
WO2011153319A1 (en) 2011-12-08
PL2576586T3 (pl) 2016-01-29
CN102985438A (zh) 2013-03-20
JP2013527243A (ja) 2013-06-27
EP2576586A1 (en) 2013-04-10
CA2801491A1 (en) 2011-12-08
SMT201500272B (it) 2016-01-08
RS54239B1 (sr) 2015-12-31
DK2576586T3 (en) 2015-11-23
US8802661B2 (en) 2014-08-12
SI2576586T1 (sl) 2015-11-30
ES2548905T3 (es) 2015-10-21
US20120142653A1 (en) 2012-06-07
TW201201792A (en) 2012-01-16
EA201270800A1 (ru) 2013-04-30
CA2801491C (en) 2018-01-23
HUE026662T2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
JP5755731B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド
JP6000283B2 (ja) Hiv成熟阻害剤としてのc−3修飾ベツリン酸誘導体のc−28アミン
JP5752789B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
JP6155285B2 (ja) Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド
JP6212545B2 (ja) Hiv成熟阻害活性を有するc−17二環式アミンのトリテルペノイド
JP6001560B2 (ja) Hiv成熟阻害活性を有するc−17およびc−3修飾トリテルペノイド
JP6186012B2 (ja) C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
AU2014215468B2 (en) C-19 modified triterpenoids with HIV maturation inhibitory activity
KR102411082B1 (ko) 할로알킬 치환기를 지니는 비­방향족 고리에 의해 위치 3에서 치환된,hiv 성숙화 억제 활성을 갖는 트리테르페노이드
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity
JP2017533934A (ja) C17アリール置換ベツリン酸類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150527

R150 Certificate of patent or registration of utility model

Ref document number: 5755731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees